Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ANT006
MIFTS: 59

Antiphospholipid Syndrome

Categories: Rare diseases, Immune diseases, Genetic diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Antiphospholipid Syndrome

About this section

MalaCards integrated aliases for Antiphospholipid Syndrome:

Name: Antiphospholipid Syndrome 12 76 53 25 54 37 55 44 15 73
Antiphospholipid Antibody Syndrome 12 53 25 63
Hughes Syndrome 53 25 54
Familial Antiphospholipid Syndrome 53 73
Acromegaloid Facial Appearance Syndrome 73
Lupus Anticoagulant, Familial 53
Anti-Phospholipid Syndrome 25
Aps 53

Classifications:

MalaCards categories:
Global: Rare diseases Genetic diseases
Anatomical: Immune diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:2988
ICD10 33 D68.61
MeSH 44 D016736
NCIt 50 C61283
KEGG 37 H01697
Sources

Summaries for Antiphospholipid Syndrome

About this section
NINDS : 54 Antiphospholipid syndrome (APS) is an autoimmune disorder caused when antibodies -- immune system cells that fight off bacteria and viruses -- mistakenly attack healthy body tissues and organs.  In APS, specific antibodies activate the inner lining of blood vessels, which leads to the formation of blood clots in arteries or veins.  APS is sometimes called “sticky blood syndrome,” because of the increased tendency to form blood clots in the veins and arteries.  The symptoms of APS are due to the abnormal blood clotting.  Clots can develop in the veins of the legs and lungs, or in the placenta of pregnant women.  One of the most serious complications of APS occurs when a clot forms in the brain and causes a stroke.  Other neurological symptoms include chronic headaches, dementia (similar to the dementia of Alzheimer’s disease), and seizures.  Infrequently, individuals will develop chorea (a movement disorder in which the body and limbs writhe uncontrollably), cognitive dysfunction (such as poor memory), transverse myelitis, depression or psychosis, optic neuropathy, or sudden hearing loss.  In pregnant women, clots in the placenta can cause miscarriages.  APS is diagnosed by the presence of a positive antiphospholipid antibody and either a history of blood clots in an artery or vein or a history of multiple miscarriages or other pregnancy problems.  Some individuals will have a characteristic lacy, net-like red rash called livedo reticularis over their wrists and knees. 

MalaCards based summary : Antiphospholipid Syndrome, also known as antiphospholipid antibody syndrome, is related to catastrophic antiphospholipid syndrome and splenic infarction, and has symptoms including unspecified visual loss An important gene associated with Antiphospholipid Syndrome is APOH (Apolipoprotein H), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Collagen chain trimerization. The drugs Dalteparin and Enoxaparin have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and heart, and related phenotypes are homeostasis/metabolism and hematopoietic system

Disease Ontology : 12 A hypersensitivity reaction type II disease that is characterized by recurrent venous or arterial thrombosis and/or fetal losses associated with characteristic elevated levels of antibodies directed against membrane anionic phospholipids (anticardiolipin).

Genetics Home Reference : 25 Antiphospholipid syndrome is a disorder characterized by an increased tendency to form abnormal blood clots (thromboses) that can block blood vessels. This clotting tendency is known as thrombophilia. In antiphospholipid syndrome, the thromboses can develop in nearly any blood vessel in the body, but most frequently occur in the vessels of the lower limbs. If a blood clot forms in the vessels in the brain, blood flow is impaired and can lead to stroke. Antiphospholipid syndrome is an autoimmune disorder. Autoimmune disorders occur when the immune system attacks the body's own tissues and organs.

NIH Rare Diseases : 53 Antiphospholipid syndrome (APS) is an autoimmune disorder. Signs and symptoms vary, but may include blood clots, miscarriage, rash, chronic headaches, dementia, and seizures. APS occurs when your body's immune system makes antibodies that attack phospholipids. Phospholipids are a type of fat found in all living cells, including blood cells and the lining of blood vessels. Most cases of APS occur in people with no family history of the disorder, however there are rare cases of APS clustering in a family. A widely accepted explanation for APS is that it is caused by a combination of genemutations (making one more susceptible to APS) and an environmental exposure (such as to a virus). Currently there is not a cure for APS. The goal of treatment is to prevent blood clots from forming and to keep existing clots from getting larger.

PubMed Health : 63 About antiphospholipid antibody syndrome: Antiphospholipid (AN-te-fos-fo-LIP-id) antibody syndrome (APS) is an autoimmune disorder. Autoimmune disorders occur if the body's immune system makes antibodies that attack and damage tissues or cells. Antibodies are a type of protein. They usually help defend the body against infections. In APS, however, the body makes antibodies that mistakenly attack phospholipids—a type of fat. Phospholipids are found in all living cells and cell membranes, including blood cells and the lining of blood vessels.When antibodies attack phospholipids, cells are damaged. This damage causes blood clots to form in the body's arteries and veins. (These are the vessels that carry blood to your heart and body.)Usually, blood clotting is a normal bodily process. Blood clots help seal small cuts or breaks on blood vessel walls. This prevents you from losing too much blood. In APS, however, too much blood clotting can block blood flow and damage the body's organs.

Wikipedia : 76 Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune,... more...

Sources

Related Diseases for Antiphospholipid Syndrome

About this section

Diseases in the Antiphospholipid Syndrome family:

Antiphospholipid Syndrome, Familial

Diseases related to Antiphospholipid Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 483)
# Related Disease Score Top Affiliating Genes
1 catastrophic antiphospholipid syndrome 32.1 ADAMTS13 APOH CD40LG F3 F5 MTHFR
2 splenic infarction 31.0 APOH F2
3 syphilis 30.2 APOH CD40LG CD79A
4 endocarditis 30.1 APOH F2 PLAT SERPINC1
5 arteritic anterior ischemic optic neuropathy 30.1 F2 F5 MTHFR
6 cerebral sinovenous thrombosis 30.0 APOH F2 F3 F5
7 coronary thrombosis 30.0 F3 PLAT SERPINC1
8 livedoid vasculopathy 29.6 APOH CD40LG F2 F5 MTHFR
9 sneddon syndrome 29.6 APOH F2 F5 SERPINC1
10 nonarteritic anterior ischemic optic neuropathy 29.5 F2 F5 MTHFR SERPINC1
11 hepatic infarction 29.4 APOH F2 F3 MTHFR SERPINC1
12 primary biliary cirrhosis 29.4 CD40LG CD79A F2
13 patent foramen ovale 29.4 F2 F5 MTHFR SERPINC1
14 ischemic colitis 29.3 APOH F2 F5 SERPINC1
15 takayasu arteritis 29.3 CD40LG SELE THBD
16 retinal artery occlusion 29.3 APOH F2 F5 MTHFR SERPINC1
17 sagittal sinus thrombosis 29.3 F2 F3 F5 SERPINC1
18 connective tissue disease 29.3 ADAMTS13 APOH CD40LG
19 acute myocardial infarction 29.3 F3 PLAT SELP SERPINC1
20 placenta disease 29.2 APOH F3 F5 MTHFR SERPINC1
21 heparin-induced thrombocytopenia 29.2 CD40LG F10 F3 SELP SERPINC1
22 sudden sensorineural hearing loss 29.2 F2 F5 MTHFR SERPINC1
23 pulmonary hypertension 29.2 F3 PLAT SERPINC1 THBD
24 ischemic optic neuropathy 29.1 APOH F2 F5 MTHFR SERPINC1
25 retinal vein occlusion 29.0 APOH F2 F5 MTHFR SERPINC1
26 protein s deficiency 28.9 APOH F2 F3 F5 MTHFR SERPINC1
27 raynaud phenomenon 28.9 APOH THBD
28 eclampsia 28.8 F2 F5 MTHFR SERPINC1 THBD
29 spinal cord infarction 28.8 APOH F2 F5 MTHFR SERPINC1
30 budd-chiari syndrome 28.8 APOH F2 F3 F5 MTHFR SERPINC1
31 central retinal vein occlusion 28.8 APOH F2 F5 MTHFR SERPINC1
32 arteriosclerosis 28.7 F3 SELE SELP THBD
33 branch retinal artery occlusion 28.6 APOH CD40LG F2 F3 MTHFR SERPINC1
34 factor x deficiency 28.6 F10 F2 F3 F5 SERPINC1
35 thrombophlebitis 28.5 APOH F2 F5 MTHFR PLAT SERPINC1
36 vasculitis 28.5 APOH CD40LG CD79A SELE THBD
37 antithrombin iii deficiency 28.4 APOH F10 F2 F5 MTHFR SERPINC1
38 protein c deficiency 28.4 F2 F5 MTHFR SERPINC1 THBD
39 retinal vascular occlusion 28.4 APOH F2 F5 MTHFR SELP SERPINC1
40 portal vein thrombosis 28.4 APOH F2 F5 MTHFR SELP SERPINC1
41 intracranial hypertension 28.3 APOH F2 F3 F5 MTHFR SERPINC1
42 prothrombin deficiency 28.1 APOH F2 F3 F5 SERPINC1 THBD
43 marantic endocarditis 27.9 F2 F3 MTHFR PLAT SERPINC1 THBD
44 pulmonary embolism 27.6 APOH F10 F2 F3 F5 MTHFR
45 systemic lupus erythematosus 27.5 ADAMTS13 APOH CD40LG CD79A F3 SELE
46 thrombotic thrombocytopenic purpura 27.5 ADAMTS13 APOH F3 SELE SELP THBD
47 arteries, anomalies of 27.3 F2 F3 MTHFR PLAT SELE SELP
48 thrombophilia due to thrombin defect 27.1 APOH F10 F2 F3 F5 MTHFR
49 thrombosis 27.0 APOH F10 F2 F3 F5 MTHFR
50 peripheral vascular disease 26.8 F2 F3 PLAT SELE SELP SERPINC1

Graphical network of the top 20 diseases related to Antiphospholipid Syndrome:



Diseases related to Antiphospholipid Syndrome
Sources

Symptoms & Phenotypes for Antiphospholipid Syndrome

About this section

UMLS symptoms related to Antiphospholipid Syndrome:


unspecified visual loss

MGI Mouse Phenotypes related to Antiphospholipid Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.28 PLAT F2 ADAMTS13 F3 APOH CD40LG
2 hematopoietic system MP:0005397 10.2 F2 ADAMTS13 ANXA5 F3 CD40LG CD79A
3 cardiovascular system MP:0005385 10.18 F10 F2 F3 CD40LG F5 PLAT
4 immune system MP:0005387 10.14 F2 ADAMTS13 ANXA5 F3 CD40LG CD79A
5 mortality/aging MP:0010768 10.07 F10 F2 ADAMTS13 F3 APOH CD40LG
6 integument MP:0010771 10.02 F2 F3 CD40LG F5 MTHFR THBD
7 nervous system MP:0003631 9.85 MTHFR F2 F3 CD40LG F5 CD79A
8 liver/biliary system MP:0005370 9.8 F5 CD79A SERPINC1 THBD SELE SELP
9 normal MP:0002873 9.5 ADAMTS13 F2 ANXA5 F3 CD79A THBD
10 vision/eye MP:0005391 9.17 MTHFR ADAMTS13 F3 PLAT SELE SELP
Sources

Drugs & Therapeutics for Antiphospholipid Syndrome

About this section

PubMedHealth treatment related to Antiphospholipid Syndrome: 63

Antiphospholipid antibody syndrome (APS) has no cure. However, medicines can help prevent complications. The goals of treatment are to prevent blood clots from forming and keep existing clots from getting larger.You may have APS and another autoimmune disorder, such as lupus. If so, it's important to control that condition as well. When the other condition is controlled, APS may cause fewer problems.Research is ongoing for new ways to treat APS.

Drugs for Antiphospholipid Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 103)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dalteparin Approved Phase 4,Phase 2,Early Phase 1,Not Applicable 9005-49-6
2
Enoxaparin Approved Phase 4,Phase 2,Early Phase 1 9005-49-6 772
3
Heparin Approved, Investigational Phase 4,Phase 1,Phase 2,Early Phase 1,Not Applicable 9005-49-6 772 46507594
4
Rivaroxaban Approved Phase 4,Phase 3 366789-02-8
5
Acetaminophen Approved Phase 4,Phase 1,Not Applicable 103-90-2 1983
6
Warfarin Approved Phase 4,Phase 3,Not Applicable 81-81-2 6691 54678486
7
Apixaban Approved Phase 4 503612-47-3 10182969
8
Serine Approved, Nutraceutical Phase 4,Phase 3 56-45-1 5951
9
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
10
leucovorin Approved, Nutraceutical Phase 4 58-05-9 143 6006
11 Vaccines Phase 4,Phase 2
12 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Antibodies, Antiphospholipid Phase 4,Phase 3,Phase 2,Not Applicable
14 Anticoagulants Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
15 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 calcium heparin Phase 4,Phase 1,Phase 2,Early Phase 1,Not Applicable
17 Heparin, Low-Molecular-Weight Phase 4,Phase 2,Early Phase 1,Not Applicable
18 Fibrinolytic Agents Phase 4,Phase 2,Early Phase 1,Not Applicable
19 Antithrombin III Phase 4,Phase 3,Not Applicable
20 Antithrombins Phase 4,Phase 3,Not Applicable
21 Factor Xa Inhibitors Phase 4,Phase 3
22 HIV Protease Inhibitors Phase 4,Phase 3
23
protease inhibitors Phase 4,Phase 3
24 Serine Proteinase Inhibitors Phase 4,Phase 3
25 Hematinics Phase 4
26 Micronutrients Phase 4
27 Trace Elements Phase 4
28 Vitamin B Complex Phase 4
29 Vitamins Phase 4
30 Analgesics Phase 4,Phase 2,Not Applicable,Early Phase 1
31 Analgesics, Non-Narcotic Phase 4,Phase 2,Not Applicable,Early Phase 1
32 Antipyretics Phase 4,Phase 2,Not Applicable,Early Phase 1
33 Peripheral Nervous System Agents Phase 4,Phase 2,Not Applicable,Early Phase 1
34 Folate Nutraceutical Phase 4
35 Vitamin B9 Nutraceutical Phase 4
36
Acenocoumarol Approved, Investigational Phase 3 152-72-7 9052 54676537
37
Hydroxychloroquine Approved Phase 3,Phase 2 118-42-3 3652
38 Autoantibodies Phase 3,Phase 1
39 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Anti-Infective Agents Phase 3,Phase 2
41 Antimalarials Phase 3,Phase 2
42 Antiparasitic Agents Phase 3,Phase 2
43 Antiprotozoal Agents Phase 3,Phase 2
44
Aspirin Approved, Vet_approved Phase 1, Phase 2,Phase 2,Early Phase 1,Not Applicable 50-78-2 2244
45
rituximab Approved Phase 2 174722-31-7 10201696
46
Fluvastatin Approved Phase 2 93957-54-1 1548972
47
Certolizumab pegol Approved Phase 2 428863-50-7
48 Calcium, Dietary Phase 2,Early Phase 1,Not Applicable
49 Anticholesteremic Agents Phase 2
50 Antimetabolites Phase 2

Interventional clinical trials:

(show top 50) (show all 64)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
2 Rivaroxaban for Antiphospholipid Antibody Syndrome Completed NCT02116036 Phase 4 Rivaroxaban
3 Timing of Initiation of LMWH Administration in Pregnant Women With APS Completed NCT02326051 Phase 4 Enoxaparin;Enoxaparin
4 Low Molecular Weight Heparin in Recurrent Miscarriage With Negative Antiphospholipid Antibodies Completed NCT01608347 Phase 4 LMWH+Folic acid;Folic Acid
5 Drug Interaction Between Paracetamol and Warfarin Completed NCT01104337 Phase 4 paracetamol;paracetamol;Placebo
6 Apixaban for the Secondary Prevention of Thromboembolism Among Patients With the AntiphosPholipid Syndrome Recruiting NCT02295475 Phase 4 Apixaban;Warfarin
7 Use of Warfarin After the First Trimester in Pregnant Women With APS Recruiting NCT02303171 Phase 4 Enoxaparin;Warfarin
8 Rivaroxaban for Patients With Antiphospholipid Syndrome Completed NCT02926170 Phase 3 Rivaroxaban;acenocumarol
9 Hydroxychloroquine for Prevention of Recurrent Miscarriage. Recruiting NCT03165136 Phase 3 Hydroxychloroquine;Placebo
10 Hydroxychloroquine Versus Placebo: Impact on Thrombotic Relapse in Primary Antiphospholipid Syndrome Not yet recruiting NCT03540810 Phase 3 Hydroxychloroquine;Placebo
11 Rivaroxaban in Thrombotic Antiphospholipid Syndrome Terminated NCT02157272 Phase 3 Experimental: Rivaroxaban
12 Hydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive Patients Terminated NCT01784523 Phase 3 Hydroxychloroquine
13 Steroids and Antiphospholipid Syndrome- Related Pregnancy Loss Unknown status NCT00180778 Phase 1, Phase 2 Low dose steroids
14 A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome Completed NCT00537290 Phase 2 Rituximab
15 Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients Completed NCT00674297 Phase 2 Fluvastatin
16 Low-molecular-weight Heparin (LMWH) Versus Unfractionated Heparin (UFH) in Pregnant Women With Recurrent Abortion Secondary to Antiphospholipid Syndrome Completed NCT01051778 Phase 2 enoxaparin 40mg plus low dose aspirin;Heparin calcium5,000 U twice daily plus low dose aspirin
17 Aspirin in Asymmetrically Intrauterine Growth Completed NCT03038607 Phase 2 Aspirin
18 Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children Completed NCT00502593 Phase 2
19 Study of the Efficiency of Hydroxychloroquine on the Endothelial Dysfunction and Its Vascular Consequences During the Antiphospholipid Syndrome Recruiting NCT02595346 Phase 2 Hydroxychloroquine;placebo
20 IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy Recruiting NCT03152058 Phase 2 Certolizumab Pegol
21 Eculizumab to Enable Renal Transplantation in Patients With History of Catastrophic Antiphospholipid Antibody Syndrome Active, not recruiting NCT01029587 Phase 2 Eculizumab
22 Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome Terminated NCT02128269 Phase 2
23 Infections and Autoimmunity: Autobodies Screening in Multiple Sclerosis Unknown status NCT00230204 Phase 1
24 Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases Terminated NCT00849745 Phase 1
25 Hematopoietic Stem Cell Transplantation in Patients With Antiphospholipid Syndrome Withdrawn NCT00278616 Phase 1
26 Preconceptional Thromboprophylaxis in Recurrent PREGNANCY LOSSES Caused by Antiphospholipid Syndrome Unknown status NCT01661439 low molecular weight heparin (enoxeparine)
27 Antiphospholipid Antibodies and Early Severe Preeclampsia. Unknown status NCT01538121
28 Antiphospholipid Antibodies and Fetal Growth Restriction Unknown status NCT01538134
29 Longitudinal Study of the Clinical and Haematological Cause of Women With Antiphospholipid Antibodies. Unknown status NCT00180817
30 Beneficial Effects of Coenzyme Q10 Treatment on the Mitochondrial Dysfunction and Oxidative Stress Associated to Atherothrombosis Developement in Antiphospholipidid Syndrome Patients Unknown status NCT02218476 Not Applicable CoQ10;Placebo
31 The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome Unknown status NCT01818505
32 Monitoring Anticoagulant Therapy in Antiphospholipid Syndrome Completed NCT01660061
33 Antiphospholipid Syndrome Collaborative Registry (APSCORE) Completed NCT00076713
34 Reliability of Point-of-care INR Measurements in Patients With Antiphospholipid-antibody Syndrome Treated With Warfarin Completed NCT00878137
35 The Prognostic Value of PGF and sFlt1 Variations Induced by the First Low-molecular-weight-heparin Injections in Women With Obstetrical Antiphospholipids Antibody Syndrome Starting a New Pregnancy and Following Treatment in Accordance With International R Completed NCT02855047
36 Assessment of the Prevalence of Major Psychiatric Disorders in a Cohort of Women With Clinical Criteria Corresponding to Pure, Abortive-form, Obstetrical, Antiphospholipid Syndrome Completed NCT02833194
37 CoaguChek XS in Antiphospholipid Antibody Syndrome (APL) Patients Completed NCT02139072
38 Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome Completed NCT00010400 Not Applicable Cyclophosphamide;filgrastim
39 Hypercoagulable Phenotype by Thrombinography (in Presence of C Protein Dynamic Inhibitory System) Completed NCT02892565 Not Applicable
40 CI(R)CA : Coumadin Interaction With Rofecoxib, Celecoxib and Acetaminophen Completed NCT01762891 Not Applicable Celecoxib;Acetaminophen;Rofecoxib;placebo
41 Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE) Completed NCT01475149
42 Pharmacokinetics of Low Molecular Weight and Unfractionated Heparin in Pregnancy Completed NCT00721591
43 Promising Bimarker Prediction of Outcome of HELLP Syndrome. Completed NCT03246542
44 Clinical Significance of Antiphospholipid Antibodies in Healthy Subjects Completed NCT02803645 Not Applicable
45 Pharmacogenetics of Warfarin in Puerto Ricans. Completed NCT01318057
46 Extra Corporeal Membrane Oxygenation in the Acute Respiratory Distress Syndrome: Utility of a Biomarker to Assess the Membrane Efficiency in Improving Oxygenation Completed NCT02879344 Not Applicable
47 Ocular Findings in Women With Primary Antiphospholipid Syndrome Recruiting NCT03459508
48 Register for Pediatric Patients With Antiphospholipid Syndrome (APS): European Project Extended Internationally Study Recruiting NCT00616317
49 Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome Recruiting NCT00482794
50 Register of Patients With Anti-Phospholipids Syndrome (APS) and/or Systemic Lupus Erythematosus (SLE) Recruiting NCT02782039

Search NIH Clinical Center for Antiphospholipid Syndrome

Cochrane evidence based reviews: antiphospholipid syndrome

Sources

Genetic Tests for Antiphospholipid Syndrome

About this section
Sources

Anatomical Context for Antiphospholipid Syndrome

About this section

MalaCards organs/tissues related to Antiphospholipid Syndrome:

41
Brain, Testes, Heart, Endothelial, Placenta, Lung, Monocytes
Sources

Publications for Antiphospholipid Syndrome

About this section

Articles related to Antiphospholipid Syndrome:

(show top 50) (show all 1538)
# Title Authors Year
1
Dyspnea and Edema in a Woman With Antiphospholipid Syndrome. ( 29955809 )
2018
2
Antiphospholipid Syndrome Complicating Pneumococcal Meningitis. ( 29845960 )
2018
3
Prothrombin conversion is accelerated in the antiphospholipid syndrome and insensitive to thrombomodulin. ( 29895622 )
2018
4
Anti-annexin A5 antibodies and 25-hydroxy-cholecalciferol in female patients with primary antiphospholipid syndrome. ( 29948348 )
2018
5
Catastrophic antiphospholipid syndrome and pregnancy. Clinical report. ( 29284338 )
2018
6
Catastrophic antiphospholipid syndrome and pregnancy. ( 29179957 )
2018
7
Nonbacterial thrombotic endocarditis in a patient with primary antiphospholipid syndrome. ( 29977578 )
2018
8
Anticoagulation in a patient with antiphospholipid syndrome and a mechanical heart valve: a case study. ( 29939846 )
2018
9
Direct oral anticoagulant use in patients with thrombophilia, antiphospholipid syndrome or venous thrombosis of unusual sites: A narrative review. ( 29402471 )
2018
10
A case of extreme weight loss due to mesenteric ischemia and antiphospholipid syndrome. ( 29881563 )
2018
11
Extra-criteria manifestations of antiphospholipid syndrome: Risk assessment and management. ( 29395258 )
2018
12
Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases? ( 29891914 )
2018
13
Difficulties in the treatment of recurring diffuse alveolar hemorrhage accompanying primary antiphospholipid syndrome: a case report and literature review. ( 29960279 )
2018
14
The antiphospholipid syndrome and its 'non-criteria' manifestations. ( 29449418 )
2018
15
Decreased hippocampal cell proliferation in mice with experimental antiphospholipid syndrome. ( 29936552 )
2018
16
Reversible Parkinsonism and Multiple Cerebral Infarctions after Pulmonary Endarterectomy in a Patient with Antiphospholipid Syndrome. ( 29321405 )
2018
17
Necrotising scleritis, keratitis and uveitis in primary antiphospholipid syndrome. ( 29764818 )
2018
18
Arterial stenosis in antiphospholipid syndrome: Update on the unrevealed mechanisms of an endothelial disease. ( 29339317 )
2018
19
Platelet-activating factor acetylhydrolase in primary antiphospholipid syndrome. ( 29429123 )
2018
20
Immunoglobulins from sera of antiphospholipid syndrome patients are internalized in the HTR-8/SVneo cell line and cytotrophoblast in culture. ( 29960807 )
2018
21
Primary antiphospholipid syndrome and antiphospholipid syndrome associated to systemic lupus: Are they different entities? ( 29885541 )
2018
22
Manuscript title: Cardiac and neurological involvement in Antiphospholipid syndrome: a case of a 47-year-old woman with nonbacterial thrombotic endocarditis and cognitive impairment. ( 29936322 )
2018
23
Oromandibular chorea in antiphospholipid syndrome. ( 29305492 )
2018
24
Antiphospholipid Syndrome Nephropathy: From Pathogenesis to Treatment. ( 29904380 )
2018
25
Genetic risk factors in thrombotic primary antiphospholipid syndrome: A systematic review with bioinformatic analyses. ( 29355608 )
2018
26
The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review. ( 29779928 )
2018
27
Assessment of diagnostic methods for the detection of anticardiolipin and anti-I^eta<sub>2</sub> glycoprotein I antibodies in patients under routine evaluation for antiphospholipid syndrome. ( 29883633 )
2018
28
Microthrombotic renal involvement in an SLE patient with concomitant catastrophic antiphospholipid syndrome: the beneficial effect of rituximab treatment. ( 29635999 )
2018
29
Arterial/venous thrombosis, fetal loss and stillbirth in pregnant women with systemic lupus erythematosus versus primary and secondary antiphospholipid syndrome: a systematic review and meta-analysis. ( 29879927 )
2018
30
Therapeutic apheresis in the treatment of catastrophic antiphospholipid syndrome. ( 29478799 )
2018
31
Tolerogenic I^2-glycoprotein I DNA vaccine and FK506 as an adjuvant attenuates experimental obstetric antiphospholipid syndrome. ( 29894515 )
2018
32
Rare Presentation of Catastrophic Antiphospholipid Syndrome with Myocarditis in Post-partum Period: Case Report and Review of Literature. ( 29391679 )
2018
33
Antiphospholipid syndrome. ( 29368699 )
2018
34
McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. ( 29978552 )
2018
35
Thrombocytopenia in high-risk patients with antiphospholipid syndrome. ( 29316193 )
2018
36
Recent Developments in Antiphospholipid Antibodies and the Antiphospholipid Syndrome. ( 29940673 )
2018
37
A Patient With Remote Heparin-Induced Thrombocytopenia and Antiphospholipid Syndrome Requiring Cardiopulmonary Bypass: Do Current Guidelines Apply? ( 29871549 )
2018
38
Antiphosphatidylserine/prothrombin (aPS/PT) antibodies are associated with Raynaud phenomenon and migraine in primary thrombotic antiphospholipid syndrome. ( 29338587 )
2018
39
Antiphospholipid syndrome. ( 29321639 )
2018
40
Antiphospholipid syndrome, &amp;quot;the best prophet of the future&amp;quot;. ( 29385876 )
2018
41
Clinical Report of Probable Catastrophic Antiphospholipid Syndrome in Pregnancy. ( 29808136 )
2018
42
Immunomodulation in the Treatment of Refractory Catastrophic Antiphospholipid Syndrome. ( 29805821 )
2018
43
Immunoproteomic identification of anti-C9 autoimmune antibody in patients with seronegative obstetric antiphospholipid syndrome. ( 29894483 )
2018
44
Pathogenic Role of Complement in Antiphospholipid Syndrome and Therapeutic Implications. ( 29971066 )
2018
45
Antiphospholipid syndrome. ( 29321641 )
2018
46
Complement System Abnormalities in Patients with Atypical Hemolytic Uremic Syndrome and Catastrophic Antiphospholipid Syndrome. ( 29308852 )
2017
47
Lupus-Negative Libman-Sacks Endocarditis Complicated by Catastrophic Antiphospholipid Syndrome. ( 28515823 )
2017
48
Catastrophic antiphospholipid syndrome: A case with unusual findings revealed in autopsy and a brief literature update. ( 29308285 )
2017
49
Closing the Serological Gap in the Antiphospholipid Syndrome: The Value of &amp;quot;Non-criteria&amp;quot; Antiphospholipid Antibodies. ( 28864642 )
2017
50
Thrombotic management of antiphospholipid syndrome: Towards novel targeted therapies. ( 28056758 )
2017
Sources

Variations for Antiphospholipid Syndrome

About this section

Copy number variations for Antiphospholipid Syndrome from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 160790 22 16300000 24300000 Deletion Hughes'' syndrome
Sources

Expression for Antiphospholipid Syndrome

About this section
Search GEO for disease gene expression data for Antiphospholipid Syndrome.
Sources

Pathways for Antiphospholipid Syndrome

About this section

Pathways related to Antiphospholipid Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Response to elevated platelet cytosolic Ca2+ 66
Show member pathways
 12.97 ANXA5 APOH F10 F2 F3 F5
2
Collagen chain trimerization 66
Show member pathways
 12.46 F10 F2 F3 F5 SERPINC1 THBD
3
Cell surface interactions at the vascular wall 66
Show member pathways
 11.88 F2 SELE SELP THBD
4
Cell adhesion molecules (CAMs) 37
11.81 CD40LG SELE SELP
5
Fluid shear stress and atherosclerosis 37
11.78 PLAT SELE THBD
6
Formation of Fibrin Clot (Clotting Cascade) 66
Show member pathways
 11.7 F10 F2 F3 F5 PLAT SERPINC1
7
AGE-RAGE signaling pathway in diabetic complications 37
11.58 F3 SELE THBD
8
Complement and coagulation cascades 1 37
11.31 F10 F2 F3 F5 PLAT SERPINC1
9
Malaria 37
11.23 CD40LG SELE SELP
10
Warfarin Pathway, Pharmacodynamics 61
10.61 F10 F2
Sources

GO Terms for Antiphospholipid Syndrome

About this section

Cellular components related to Antiphospholipid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.8 ADAMTS13 APOH CD40LG F3 PLAT THBD
2 endoplasmic reticulum lumen GO:0005788 9.65 ADAMTS13 F10 F2 F5 SERPINC1
3 extracellular region GO:0005576 9.65 ADAMTS13 ANXA5 APOH CD40LG F10 F2
4 external side of plasma membrane GO:0009897 9.55 ANXA5 CD40LG CD79A F2 SELP
5 intrinsic component of external side of plasma membrane GO:0031233 9.37 F10 F3
6 extracellular space GO:0005615 9.36 ADAMTS13 APOH CD40LG F2 F3 F5

Biological processes related to Antiphospholipid Syndrome according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 leukocyte migration GO:0050900 9.76 F2 SELE SELP THBD
2 platelet activation GO:0030168 9.72 ADAMTS13 CD40LG F2
3 platelet degranulation GO:0002576 9.71 ANXA5 APOH F5 SELP
4 blood coagulation GO:0007596 9.61 ADAMTS13 ANXA5 F10 F2 F3 F5
5 fibrinolysis GO:0042730 9.57 F2 PLAT
6 leukocyte tethering or rolling GO:0050901 9.56 SELE SELP
7 negative regulation of blood coagulation GO:0030195 9.54 APOH THBD
8 leukocyte cell-cell adhesion GO:0007159 9.54 CD40LG SELE SELP
9 positive regulation of blood coagulation GO:0030194 9.52 APOH F2
10 plasminogen activation GO:0031639 9.51 APOH PLAT
11 blood coagulation, intrinsic pathway GO:0007597 9.5 APOH F10 F2
12 peptidyl-glutamic acid carboxylation GO:0017187 9.49 F10 F2
13 negative regulation of platelet activation GO:0010544 9.48 F2 THBD
14 blood coagulation, extrinsic pathway GO:0007598 9.43 F10 F3
15 regulation of blood coagulation GO:0030193 9.43 APOH F2 SERPINC1
16 negative regulation of fibrinolysis GO:0051918 9.33 APOH F2 THBD
17 hemostasis GO:0007599 9.23 ADAMTS13 ANXA5 F10 F2 F3 F5

Molecular functions related to Antiphospholipid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serine-type endopeptidase activity GO:0004252 9.56 F10 F2 F3 PLAT
2 heparin binding GO:0008201 9.46 APOH F2 SELP SERPINC1
3 calcium ion binding GO:0005509 9.43 ADAMTS13 ANXA5 F10 F2 SELP THBD
4 oligosaccharide binding GO:0070492 9.37 SELE SELP
5 sialic acid binding GO:0033691 9.32 SELE SELP
6 phospholipid binding GO:0005543 8.92 ANXA5 APOH F10 F3
7 protein binding GO:0005515 10.25 ADAMTS13 ANXA5 APOH CD40LG CD79A F10
Sources

Sources for Antiphospholipid Syndrome

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....